Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-11-15 13:30 |
Cantargia avancerar utvecklingen av antikroppen CAN04 efter positivt pre-IND mö…
|
Swedish | 62.3 KB | ||
| 2019-11-15 13:30 |
Cantargia advance antibody CAN04 development after positive pre-IND meeting
|
English | 144.7 KB | ||
| 2019-11-15 08:30 | Swedish | 438.8 KB | |||
| 2019-11-15 08:30 | English | 506.6 KB | |||
| 2019-10-10 12:00 |
Cantargia reports filing of opposition against Cantargia patent in Europe
|
English | 163.0 KB | ||
| 2019-10-10 12:00 |
Cantargia meddelar att en opposition lämnats in mot ett av Cantargias patent i …
|
Swedish | 59.7 KB | ||
| 2019-09-04 15:30 |
Cantargia ansöker om pre-IND möte för CAN04 med FDA
|
Swedish | 156.6 KB | ||
| 2019-09-04 15:30 |
Cantargia submits request for pre-IND meeting on CAN04 with US FDA
|
English | 157.0 KB | ||
| 2019-08-23 13:00 |
Cantargia announce positive preclinical data on CAN04 in bladder cancer
|
English | 110.2 KB | ||
| 2019-08-23 13:00 |
Cantargia meddelar positiva prekliniska data för CAN04 i urinblåsecancer
|
Swedish | 81.9 KB | ||
| 2019-08-22 08:30 | Swedish | 385.7 KB | |||
| 2019-08-22 08:30 | English | 447.0 KB | |||
| 2019-07-04 08:30 |
Cantargia meddelar att CAN04 monoterapi-armen i den pågående fas IIa kliniska p…
|
Swedish | 164.9 KB | ||
| 2019-07-04 08:30 |
Cantargia announce full recruitment of CAN04 monotherapy arm in ongoing phase I…
|
English | 164.4 KB | ||
| 2019-06-13 09:00 |
Cantargias styrelseledamot och grundare Thoas Fioretos säljer 250 000 Cantargia…
|
Swedish | 131.0 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
